Abstract Purpose of Review This study is to highlight the incidence of corneal
pseudomicrocysts in FDA-approved antibody–drug conjugates (ADCs), and success of …

Antibody-drug conjugates (ADCs) are a growing class of chemotherapeutic agents for the
purpose of treating cancers that often have relapsed or failed first-and second-line …

This article reviews ocular adverse events (AEs) reported in association with administration
of antibody–drug conjugates (ADCs) in human clinical trials. References reporting ocular …

This report highlights corneal epithe-lial changes in 3 patients receiving different antibody-
drug conjugate (ADC) therapies that inhibit tubulin assembly: anetumab ravtansine for …

Purpose: Antibody–drug conjugates (ADCs) are a class of cancer drug wherein some are
associated with corneal abnormalities, but there is a dearth of published information on …

Purpose: To report the histological findings and clinical course of 2 patients with microcyst-
like epithelial keratopathy (MEK) associated with antibody-drug conjugate, depatuxizumab …

Cancer treatments have recently shifted from broad-spectrum cytotoxic therapies to more
focused treatments, maximizing anti-cancerous activity while reducing toxicity to healthy …

Ocular toxicities associated with antibody drug conjugates Page 1 ICU 350601 CURRENT
OPINION Ocular toxicities associated with antibody drug conjugates Rayna F. Marshalla …

Antibody–drug conjugates consist of a monoclonal antibody attached to a cytotoxic
therapeutic molecule by a connector. This association allows a highly specific therapy …

Purpose To report 3 cases of reversible epitheliopathy induced by A166—a human
epidermal growth factor receptor (HER2)-targeted antibody-drug conjugate (ADC) therapy …